A multicenter survey of real-word data on the accessibility of specific medicines for children in ChinaRUAN Wen-yi, HUO Ji-ping, YU Biao, CAI He-ping, WANG Xiao-ling, ZHAO Zhi-gang849-855
Analysis of the factors influencing the stability of technological innovation strategic alliance in pharmaceutical industryZHU Xin-tong, HUANG Zhe856-863
The realistic dilemma and institutional optimization of the accessibility of patented medicines——a concurrent review on the operation of Medicines Patent PoolHUANGFU Jie-qiong, ZHONG Yan864-867
Evaluation considerations on post-approval changes in registration standards of recombinant biological productsZHAO Jing, QIU Xiao, WEI Wei868-873
General considerations for initiating cause inspections during the drug evaluation processHE Hui, BAN Hao, ZHOU Gang874-876
Progress in quality control of heavy metals and harmful elements in marine traditional Chinese medicine and future development directionsGUO Yuan-sheng, ZUO Tian-tian, CHEN An-zhen, JIN Hong-yu, LI Ping, MA Shuang-cheng877-884
Application of similarity algorithms in drug-target predictionZHANG Xin-you, WANG Zhi, ZHANG Chun-qiang, CHEN Hao, LI Xue-mei, ZHANG Ya-ming, ZHOU Xiao-ling885-894
Progress in clinical research of targeted drugs for HER2 positive non-small cell lung cancerLI Xi-yue, WANG Xun, ZHU Xue895-903
Research progress in therapeutic drug monitoring of ceftazidime/avibactamLIU Xiao-yang, LI Bo, CHEN Yue, LI Peng-mei904-910
Virtual patient in clinical trial simulation:concepts,models and casesWANG Si-cun, CHEN Ya-fei, GU Hao, DANG Hai-xia, LIU Jun, WANG Zhong, YU Ya-nan911-916